A Phase 1, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Single and Multiple Ascending Doses of MBX 2109 in Healthy Participants
Latest Information Update: 20 Oct 2023
At a glance
- Drugs MBX 2109 (Primary)
- Indications Hypoparathyroidism
- Focus Adverse reactions; First in man
- Sponsors MBX Biosciences
- 16 Oct 2023 According to a MBX Biosciences Media Release, the company is preparing for end of phase I meeting with the U.S. Food and Drug Administration this quarter.
- 16 Oct 2023 Results published in the MBX Biosciences Media Release.
- 03 Oct 2023 According to a MBX Biosciences Media Release, results will be featured in a late-breaking oral presentation at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting being held in Vancouver, Canada October 13-16, 2023.